Literature DB >> 16457980

PET imaging for evaluation of metastatic colorectal cancer of the liver.

Sukru Mehmet Erturk1, Tomoaki Ichikawa, Hirofumi Fujii, Seiei Yasuda, Pablo R Ros.   

Abstract

Colorectal cancer is a major cause of cancer death in Western Europe and United States; the liver is the most common site for colorectal metastases. PET has an important role in the management of patients with colorectal liver metastases. It is an effective tool to detect hepatic metastases and to monitor the response to systemic and local therapy. The major impact of PET-CT over PET alone is the improvement in the certainty of lesion location. PET-CT has the unique advantage to combine functional and anatomic imaging in an integrated scanner; it allows a thoroughly evaluation of patients with colorectal liver metastases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16457980     DOI: 10.1016/j.ejrad.2005.11.042

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  13 in total

1.  Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT.

Authors:  L Bacigalupo; S Aufort; M C Eberlé; E Assenat; M Ychou; B Gallix
Journal:  Radiol Med       Date:  2010-06-23       Impact factor: 3.469

2.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

3.  Reliability of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in the nodal staging of colorectal cancer patients.

Authors:  Hee Jung Yi; Kyung Sook Hong; Nara Moon; Soon Sup Chung; Ryung-Ah Lee; Kwang Ho Kim
Journal:  Ann Coloproctol       Date:  2014-12-31

4.  Selection for hepatic resection of colorectal liver metastases: expert consensus statement.

Authors:  Reid B Adams; Thomas A Aloia; Evelyne Loyer; Timothy M Pawlik; Bachir Taouli; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2013-02       Impact factor: 3.647

5.  Diagnostic value of FDG-PET/CT for lymph node metastasis of colorectal cancer.

Authors:  Jae Young Kwak; Jae Seung Kim; Hye Jin Kim; Hyun Kwon Ha; Chang Sik Yu; Jin Cheon Kim
Journal:  World J Surg       Date:  2012-08       Impact factor: 3.352

6.  The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI.

Authors:  G Kong; C Jackson; D M Koh; V Lewington; B Sharma; G Brown; D Cunningham; G J R Cook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-18       Impact factor: 9.236

7.  Impact of (18)F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancer.

Authors:  Brigita Paskeviciute; Tobias Bölling; Markus Brinkmann; Ganna Rudykina; Iris Ernst; Lars Stegger; Otmar Schober; Normann Willich; Matthias Weckesser; Stefan Könemann
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

8.  Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer.

Authors:  Ukihide Tateishi; Tetsuo Maeda; Tsuyoshi Morimoto; Mototaka Miyake; Yasuaki Arai; E Edmund Kim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-26       Impact factor: 9.236

Review 9.  Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection.

Authors:  Rafif E Mattar; Faisal Al-Alem; Eve Simoneau; Mazen Hassanain
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

10.  18F-FDG PET/CT performed immediately after percutaneous ablation to evaluate outcomes of the procedure: preliminary results.

Authors:  Juliana Romanato; Marcos Roberto Menezes; Allan de Oliveira Santos; Regis Otaviano Franca Bezerra; Mariana Cunha Lopes Lima; Elba Etchebehere
Journal:  Radiol Bras       Date:  2019 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.